Enzymatically prepared spin labeled copolymers of (U)n were tested for their ability to direct polyphenylalanine synthesis in vitro using E. coli B enzymes and ribosomes. Spin labeling of the C5 position using (RUGT,U)n (1:100) or (RUTT,U)n (1:100) did not alter the amount of polyphenylalanine formed in comparison to (U)n. In contrast, the C4 spin labeled copolymer (ls4U,U)n (1:100) reduced phenylalanine incorporation by 70-75% of the (U)n control levels. ESR monitoring of competitive ribosome binding to equimolar mixtures of polynucleotides was demonstrated with the macromolecular probe (DUTT,dT)n (1:100), the DNA analogue of (RUTT,U)n. The ESR competition approach showed that the affinity of the ribosomes was essentially the same for (dT)n, (A,U,G)n, and (A,U,G)n + tRNArmet.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC327534PMC
http://dx.doi.org/10.1093/nar/9.20.5483DOI Listing

Publication Analysis

Top Keywords

spin labeled
8
protein synthesis
4
synthesis competitive
4
competitive esr
4
esr binding
4
binding studies
4
studies coli
4
coli ribosomes
4
ribosomes spin-labeled
4
spin-labeled polynucleotides
4

Similar Publications

The formation of protein condensates (droplets) via liquid-liquid phase separation (LLPS) is a commonly observed phenomenon in vitro. Changing the environmental properties with cosolutes, molecular crowders, protein partners, temperature, pressure, etc. has been shown to favor or disfavor the formation of protein droplets by fine-tuning the water-water, water-protein, and protein-protein interactions.

View Article and Find Full Text PDF

The alteration of neurovascular coupling (NVC), where acute localized blood flow increases following neural activity, plays a key role in several neurovascular processes including aging and neurodegeneration. While not equivalent to NVC, the coupling between simultaneously measured cerebral blood flow (CBF) with arterial spin labeling (ASL) and blood oxygenation dependent (BOLD) signals, can also be affected. Moreover, the acquisition of BOLD data allows the assessment of resting state (RS) fMRI metrics.

View Article and Find Full Text PDF

Blood-brain barrier (BBB) dysfunction is suggested to be a potential mediator between vascular risk factors and cognitive impairment, leading to vascular cognitive impairment. To investigate the relationships between age, sex, and vascular risk factors and BBB water permeability as well as their relationship with cognition. To measure BBB permeability, a novel arterial spin labelling MRI technique (ME-ASL) was applied to derive the time of exchange (Tex), arterial time transit (ATT), and cerebral blood flow (CBF).

View Article and Find Full Text PDF

Many protein bioconjugation strategies focus on the modification of lysine residues owing to the nucleophilicity of their amine side-chain, the generally high abundance of lysine residues on a protein's surface and the ability to form robustly stable amide-based bioconjugates. However, the plethora of solvent accessible lysine residues, which often have similar reactivity, is a key inherent issue when searching for regioselectivity and/or controlled loading of an entity. A relevant example is the modification of antibodies and/or antibody fragments, whose conjugates offer potential for a wide variety of applications.

View Article and Find Full Text PDF

Anti-amyloid therapy and cerebral blood flow changes on Magnetic Resonance Imaging: a potential longitudinal biomarker of treatment response?

AJNR Am J Neuroradiol

January 2025

From the Department of Department of Radiology, Brain Health Imaging Institute (A.R-F, J.I, S.P, M.d, G.C.C) Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA; the Department of Neurology (A.R-F), Pontificia Universidad Javeriana, Bogota, Colombia; the Department of Radiology, Division of Molecular Imaging and Therapeutics (A.R-F, J.I) Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA; the Department of Neurology (D.Z, MM, L.R, A.S.N) Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA.

Amyloid-targeting therapy has recently become widely available in the U.S. for the treatment of patients with symptomatic mild Alzheimer's disease (AD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!